da Costa, Alexandre André B. A. http://orcid.org/0000-0002-1631-0105
Chowdhury, Dipanjan http://orcid.org/0000-0001-5645-3752
Shapiro, Geoffrey I.
D’Andrea, Alan D. http://orcid.org/0000-0001-6168-6294
Konstantinopoulos, Panagiotis A. http://orcid.org/0000-0002-1032-1479
Article History
Accepted: 25 August 2022
First Online: 6 October 2022
Competing interests
: G.I.S. is a consultant/advisory board member for Lilly, Sierra Oncology, Merck-EMD Serono, Pfizer, Astex, Almac, Roche, Bicycle Therapeutics, Fusion Pharmaceuticals, G1 Therapeutics, Bayer, Ip-sen, Cybrexa Therapeutics, Angiex, Daiichi Sankyo and Seattle Genetics, and reports receipt of commercial research grants from Lilly, Sierra Oncology, Merck-EMD Serono and Merck & Co. P.A.K. reports participation in advisory boards from GlaxoSmithKline/Tesaro, Merck, AstraZeneca and Bayer. A.D.D. is a consultant and/or advisory board member for AstraZeneca, Bayer AG, Cedilla Therapeutics, Celgene, Cyteir Therapeutics, Epizyme, GalaxoSmithKline, Ideaya, Impact Therapeutics, LAV Global Management Company Limited. D.C. and A.A.B.A.C. declare no competing interests.